Physician profile
Robin D Snead
NPI 1972695526
$1,631.00
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $481 · 2021: $282.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $301.02 | 2019-2020 | |
| Lilly USA, LLC | $232.03 | 2019-2021 | |
| Pfizer INC. | $231.01 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $170.16 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $152.45 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $72.36 | 2019-2021 | |
| Amgen INC. | $69.91 | 2019-2020 | |
| Amarin Pharma, INC. | $66.01 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $56.89 | 2020-2021 | |
| Glaxosmithkline, LLC. | $50.14 | 2020-2021 | |
| Zyla Life Sciences, INC. | $37.93 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.08 | 2019 | |
| Corcept Therapeutics | $36.88 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.77 | 2019-2021 | |
| Optinose US, INC. | $24.23 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $21.08 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.40 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.21 | 2019 | |
| Assertio Therapeutics, INC. | $11.44 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Snead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.